Screening for HPV-related oropharyngeal, anal, and penile cancers in middle-aged men: Initial report from the HOUSTON clinical trial

Kristina R. Dahlstrom; Karen S. Anderson; Ming Guo; Michael C. Kwon; Craig A. Messick; Curtis A. Pettaway; Nancy Asomaning; Marika Hopper; Anthony Price; Li Xu; Andrew T. Day; Ann M. Gillenwater; Erich M. Sturgis

doi:10.1016/j.oraloncology.2021.105397

Screening for HPV-related oropharyngeal, anal, and penile cancers in middle-aged men: Initial report from the HOUSTON clinical trial

Kristina R. Dahlstrom, Karen S. Anderson, Ming Guo, Michael C. Kwon, Craig A. Messick, Curtis A. Pettaway, Nancy Asomaning, Marika Hopper, Anthony Price, Li Xu, Andrew T. Day, Ann M. Gillenwater, Erich M. Sturgis

Research output: Contribution to journal › Article › peer-review

11 Scopus citations

Abstract

Background: The Human papillomavirus (HPV)-related Oropharyngeal and Uncommon Cancers Screening Trial of Men (HOUSTON) was designed to determine the prevalence of IgG antibodies to HPV type 16 E proteins (HPV16EAbs), to screen for persistence of HPV and/or detect HPV-related premalignancies and cancers, and to assess acceptance of screening among middle-aged men. Methods: HOUSTON consists of a cross-sectional study and a longitudinal cohort study of men aged 50–64 years. Serologic HPV16EAb status and oral rinse HPV16 status were determined. All HPV16EAb-positive (HPV16EAb+) men and a matched cohort of HPV16EAb-negative (HPV16EAb−) men as well as all oral rinse HPV16-positive (HPV16+) men were included in the longitudinal study (blinded to their results) and underwent oropharyngeal screening every 6 months as well as one-time anal and penile screening. Results: Of 553 men enrolled in the cross-sectional study, six (1.1%) were HPV16EAb+ (two were also oral rinse HPV16+), and 41 (7.4%) were HPV16EAb− but oral rinse HPV16+. These 47 men, along with five matched controls, were invited to participate in the longitudinal study, and 42 (81%) agreed and completed baseline in-person screening, with 93% and 90% completeing 6-month and 12-month follow-up visits. One HPV16EAb+ (also oral rinse HPV16+) man, who declined participation in the longitudinal study, presented 4 months after enrollment with an early-stage HPV16-related pharyngeal cancer. Additionally, one HPV16EAb+ (oral rinse HPV16−) man and two oral rinse HPV16+ (HPV16EAb−) men were diagnosed with oncogenic HPV-associated anal dysplasia. Conclusions: This biomarker panel deserves further prospective study to explore potential utility for HPV-related cancer screening among men.

Original language	English (US)
Article number	105397
Journal	Oral Oncology
Volume	120
DOIs	https://doi.org/10.1016/j.oraloncology.2021.105397
State	Published - Sep 2021

Keywords

Early detection
Human papillomavirus
Oropharyngeal cancer
Screening

ASJC Scopus subject areas

Oral Surgery
Oncology
Cancer Research

Access to Document

10.1016/j.oraloncology.2021.105397

Cite this

Dahlstrom, K. R., Anderson, K. S., Guo, M., Kwon, M. C., Messick, C. A., Pettaway, C. A., Asomaning, N., Hopper, M., Price, A., Xu, L., Day, A. T., Gillenwater, A. M., & Sturgis, E. M. (2021). Screening for HPV-related oropharyngeal, anal, and penile cancers in middle-aged men: Initial report from the HOUSTON clinical trial. Oral Oncology, 120, Article 105397. https://doi.org/10.1016/j.oraloncology.2021.105397

Dahlstrom, KR, Anderson, KS, Guo, M, Kwon, MC, Messick, CA, Pettaway, CA, Asomaning, N, Hopper, M, Price, A, Xu, L, Day, AT, Gillenwater, AM & Sturgis, EM 2021, 'Screening for HPV-related oropharyngeal, anal, and penile cancers in middle-aged men: Initial report from the HOUSTON clinical trial', Oral Oncology, vol. 120, 105397. https://doi.org/10.1016/j.oraloncology.2021.105397

@article{66c424a33bea4f04a95271f0095b873f,

title = "Screening for HPV-related oropharyngeal, anal, and penile cancers in middle-aged men: Initial report from the HOUSTON clinical trial",

abstract = "Background: The Human papillomavirus (HPV)-related Oropharyngeal and Uncommon Cancers Screening Trial of Men (HOUSTON) was designed to determine the prevalence of IgG antibodies to HPV type 16 E proteins (HPV16EAbs), to screen for persistence of HPV and/or detect HPV-related premalignancies and cancers, and to assess acceptance of screening among middle-aged men. Methods: HOUSTON consists of a cross-sectional study and a longitudinal cohort study of men aged 50–64 years. Serologic HPV16EAb status and oral rinse HPV16 status were determined. All HPV16EAb-positive (HPV16EAb+) men and a matched cohort of HPV16EAb-negative (HPV16EAb−) men as well as all oral rinse HPV16-positive (HPV16+) men were included in the longitudinal study (blinded to their results) and underwent oropharyngeal screening every 6 months as well as one-time anal and penile screening. Results: Of 553 men enrolled in the cross-sectional study, six (1.1%) were HPV16EAb+ (two were also oral rinse HPV16+), and 41 (7.4%) were HPV16EAb− but oral rinse HPV16+. These 47 men, along with five matched controls, were invited to participate in the longitudinal study, and 42 (81%) agreed and completed baseline in-person screening, with 93% and 90% completeing 6-month and 12-month follow-up visits. One HPV16EAb+ (also oral rinse HPV16+) man, who declined participation in the longitudinal study, presented 4 months after enrollment with an early-stage HPV16-related pharyngeal cancer. Additionally, one HPV16EAb+ (oral rinse HPV16−) man and two oral rinse HPV16+ (HPV16EAb−) men were diagnosed with oncogenic HPV-associated anal dysplasia. Conclusions: This biomarker panel deserves further prospective study to explore potential utility for HPV-related cancer screening among men.",

keywords = "Early detection, Human papillomavirus, Oropharyngeal cancer, Screening",

author = "Dahlstrom, {Kristina R.} and Anderson, {Karen S.} and Ming Guo and Kwon, {Michael C.} and Messick, {Craig A.} and Pettaway, {Curtis A.} and Nancy Asomaning and Marika Hopper and Anthony Price and Li Xu and Day, {Andrew T.} and Gillenwater, {Ann M.} and Sturgis, {Erich M.}",

note = "Funding Information: The authors thank Stephanie Deming, Research Medical Library, MD Anderson Cancer Center, for manuscript editing. Funding Information: This work was supported by generous philanthropic contributions from the Brown Foundation Endowed Chair (Sturgis, Baylor College of Medicine); the Christopher and Susan Damico Chair in Viral Associated Malignancies (to Sturgis, MD Anderson Cancer Center); the Stiefel Oropharyngeal Research Fund (to MD Anderson Cancer Center); and the Lyda Hill Foundation (to MD Anderson Cancer Center). Supported by the National Institutes of Health/National Cancer Institute (grant number P30CA016672 to MD Anderson Cancer Center) and used the Clinical and Translational Research Center, the Institutional Tissue Bank, and the Biostatistics Resource group. Publisher Copyright: {\textcopyright} 2021",

year = "2021",

month = sep,

doi = "10.1016/j.oraloncology.2021.105397",

language = "English (US)",

volume = "120",

journal = "Oral Oncology",

issn = "1368-8375",

publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Screening for HPV-related oropharyngeal, anal, and penile cancers in middle-aged men

T2 - Initial report from the HOUSTON clinical trial

AU - Dahlstrom, Kristina R.

AU - Anderson, Karen S.

AU - Guo, Ming

AU - Kwon, Michael C.

AU - Messick, Craig A.

AU - Pettaway, Curtis A.

AU - Asomaning, Nancy

AU - Hopper, Marika

AU - Price, Anthony

AU - Xu, Li

AU - Day, Andrew T.

AU - Gillenwater, Ann M.

AU - Sturgis, Erich M.

N1 - Funding Information: The authors thank Stephanie Deming, Research Medical Library, MD Anderson Cancer Center, for manuscript editing. Funding Information: This work was supported by generous philanthropic contributions from the Brown Foundation Endowed Chair (Sturgis, Baylor College of Medicine); the Christopher and Susan Damico Chair in Viral Associated Malignancies (to Sturgis, MD Anderson Cancer Center); the Stiefel Oropharyngeal Research Fund (to MD Anderson Cancer Center); and the Lyda Hill Foundation (to MD Anderson Cancer Center). Supported by the National Institutes of Health/National Cancer Institute (grant number P30CA016672 to MD Anderson Cancer Center) and used the Clinical and Translational Research Center, the Institutional Tissue Bank, and the Biostatistics Resource group. Publisher Copyright: © 2021

PY - 2021/9

Y1 - 2021/9

N2 - Background: The Human papillomavirus (HPV)-related Oropharyngeal and Uncommon Cancers Screening Trial of Men (HOUSTON) was designed to determine the prevalence of IgG antibodies to HPV type 16 E proteins (HPV16EAbs), to screen for persistence of HPV and/or detect HPV-related premalignancies and cancers, and to assess acceptance of screening among middle-aged men. Methods: HOUSTON consists of a cross-sectional study and a longitudinal cohort study of men aged 50–64 years. Serologic HPV16EAb status and oral rinse HPV16 status were determined. All HPV16EAb-positive (HPV16EAb+) men and a matched cohort of HPV16EAb-negative (HPV16EAb−) men as well as all oral rinse HPV16-positive (HPV16+) men were included in the longitudinal study (blinded to their results) and underwent oropharyngeal screening every 6 months as well as one-time anal and penile screening. Results: Of 553 men enrolled in the cross-sectional study, six (1.1%) were HPV16EAb+ (two were also oral rinse HPV16+), and 41 (7.4%) were HPV16EAb− but oral rinse HPV16+. These 47 men, along with five matched controls, were invited to participate in the longitudinal study, and 42 (81%) agreed and completed baseline in-person screening, with 93% and 90% completeing 6-month and 12-month follow-up visits. One HPV16EAb+ (also oral rinse HPV16+) man, who declined participation in the longitudinal study, presented 4 months after enrollment with an early-stage HPV16-related pharyngeal cancer. Additionally, one HPV16EAb+ (oral rinse HPV16−) man and two oral rinse HPV16+ (HPV16EAb−) men were diagnosed with oncogenic HPV-associated anal dysplasia. Conclusions: This biomarker panel deserves further prospective study to explore potential utility for HPV-related cancer screening among men.

AB - Background: The Human papillomavirus (HPV)-related Oropharyngeal and Uncommon Cancers Screening Trial of Men (HOUSTON) was designed to determine the prevalence of IgG antibodies to HPV type 16 E proteins (HPV16EAbs), to screen for persistence of HPV and/or detect HPV-related premalignancies and cancers, and to assess acceptance of screening among middle-aged men. Methods: HOUSTON consists of a cross-sectional study and a longitudinal cohort study of men aged 50–64 years. Serologic HPV16EAb status and oral rinse HPV16 status were determined. All HPV16EAb-positive (HPV16EAb+) men and a matched cohort of HPV16EAb-negative (HPV16EAb−) men as well as all oral rinse HPV16-positive (HPV16+) men were included in the longitudinal study (blinded to their results) and underwent oropharyngeal screening every 6 months as well as one-time anal and penile screening. Results: Of 553 men enrolled in the cross-sectional study, six (1.1%) were HPV16EAb+ (two were also oral rinse HPV16+), and 41 (7.4%) were HPV16EAb− but oral rinse HPV16+. These 47 men, along with five matched controls, were invited to participate in the longitudinal study, and 42 (81%) agreed and completed baseline in-person screening, with 93% and 90% completeing 6-month and 12-month follow-up visits. One HPV16EAb+ (also oral rinse HPV16+) man, who declined participation in the longitudinal study, presented 4 months after enrollment with an early-stage HPV16-related pharyngeal cancer. Additionally, one HPV16EAb+ (oral rinse HPV16−) man and two oral rinse HPV16+ (HPV16EAb−) men were diagnosed with oncogenic HPV-associated anal dysplasia. Conclusions: This biomarker panel deserves further prospective study to explore potential utility for HPV-related cancer screening among men.

KW - Early detection

KW - Human papillomavirus

KW - Oropharyngeal cancer

KW - Screening

UR - http://www.scopus.com/inward/record.url?scp=85109498321&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85109498321&partnerID=8YFLogxK

U2 - 10.1016/j.oraloncology.2021.105397

DO - 10.1016/j.oraloncology.2021.105397

M3 - Article

C2 - 34182223

AN - SCOPUS:85109498321

SN - 1368-8375

VL - 120

JO - Oral Oncology

JF - Oral Oncology

M1 - 105397

ER -

Screening for HPV-related oropharyngeal, anal, and penile cancers in middle-aged men: Initial report from the HOUSTON clinical trial

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this